Receive the latest updates from Matrix Medical in real time to understand product information.

On the morning of December 18, 2024, the grand opening ceremony of Beiao Building and the unveiling ceremony of the Institute of Transvascular Implanted Devices were held. Wang Jian'an, academician of the CAS Member, secretary of the Party Committee of the Second Affiliated Hospital of Zhejiang University School of Medicine, and president of the Institute of Transvascular Implantation Devices, Zheng Di, deputy secretary of the District Party Committee, director of the Management Committee, and head of the District, Ding Changyu and Wang Lisheng, district leaders, Weng Yu, head of the Science and Technology Development Department of the Institute of Science and Technology of Zhejiang University, and Ji Jian, executive vice president of the Institute of Transvascular Implantation Devices, were present.

At the ceremony, Hangzhou Matrix Medical Technology Co., Ltd. (hereinafter referred to as' Matrix Medical ') and Zhejiang Medical Second Hospital's Vascular Implant Device Research Institute reached a strategic cooperation agreement of millions of yuan on establishing a joint laboratory, jointly opening a new chapter of technological innovation and industrial upgrading.

The overall goal of the research institute is to focus on the 2030 Healthy China strategy, create a world-class clinical demand-oriented research and development center, diagnosis and treatment center, and talent highland for vascular implantation devices, and comprehensively achieve the goal of running from the forefront to the forefront in important fields. In the five-year plan, the research institute has set three core goals:

One is to achieve 95% localization of core technologies and accelerate the independent and controllable process of domestic industries;

The second is to promote a product market substitution rate of over 80%, significantly increasing the market share of domestic medical devices;

Thirdly, through technological innovation, the surgical mortality rate can be reduced by 10%, providing patients with safer and more reliable diagnosis and treatment services.

The coronary artery remodeling catheter project developed by Matrix Medical Institute is an important part of its five-year goal implementation process. This project not only showcases the company's outstanding achievements in technological innovation, but also is a key component of the core R&D program of the Second Affiliated Hospital of Zhejiang University School of Medicine's Vascular Implant Device Research Institute. The successful development of this product signifies that patients will have safer, more reliable, and significantly more effective treatment options.

Ji Peihong, founder and CEO of Matrix Medical, has successfully reached a strategic cooperation of millions with the Vascular Implant Device Research Institute of Zhejiang Medical Second Hospital in Binjiang District, Hangzhou. When introducing the situation of the research institute, Executive Vice President Ji Jian stated that the institute will fully leverage its professional advantages in the field of vascular implantation devices, work together with excellent enterprises such as Matrix Medical, and promote the progress and development of medical technology.

Matrix Medical and Zhejiang Medical Second Hospital in Binjiang District, Hangzhou City, for vascular implantation devices

The research institute has reached a strategic cooperation of millions of yuan

The achievement of this million level strategic cooperation marks a new stage in the field of vascular intervention between Matrix Medical and Zhejiang Medical Second Hospital Transvascular Implant Device Research Institute. It not only deepens the technical exchange between the two sides, but also brings safer and more effective treatment plans to patients. In the future, Ju Zheng Medical will take this opportunity to continue to deepen its cultivation in the field of vascular intervention and create an innovative intervention technology platform for the future.

The Institute of Vascular Implant Devices at Zhejiang Medical Second Hospital in Binjiang District, Hangzhou (hereinafter referred to as the "Institute"), which is the first national key laboratory for vascular implant devices in China, is a non-governmental organization supported by Zhejiang University, the Second Affiliated Hospital of Zhejiang University School of Medicine, and the Binjiang District Government of Hangzhou. The research institute is led by Academician Wang Jian'an, and the team focuses on the significant demand for vascular implantation devices. Combining with the development trend of the high-end implantable medical device industry, an innovative model driven by clinical problems and multidisciplinary linkage of medicine, engineering, and information has been established to break through the key technologies of the new generation of vascular implantation devices and create a world-class center for the research and development, diagnosis, and treatment of vascular implantation devices, as well as a talent highland.